RecruitingPhase 4NCT05267886
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Studying Cardiogenic shock
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ottawa Heart Institute Research Corporation
- Principal Investigator
- Rebecca Mathew, MDOttawa Heart Institute Research Corporation
- Intervention
- Dobutamine(drug)
- Enrollment
- 346 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (3)
- Mayo Clinic, Rochester, Minnesota, United States
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05267886 on ClinicalTrials.govOther trials for Cardiogenic shock
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07527156Prolonged Nasogastric Administration of Ketones in Decompensated Heart FailureInstitute for Clinical and Experimental Medicine
- RECRUITINGNANCT07345559Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic ShockCMC Ambroise Paré
- RECRUITINGNANCT07374289On Scene ECPR in OstravaUniversity Hospital Ostrava
- RECRUITINGNCT07402018Intra-aortic Balloon Counterpulsation (IABC) ComplianceThomas Jefferson University
- RECRUITINGNCT07309029Pre-Emptive LAVA-ECMO for Complex High-Risk TAVRAtlantic Health System
- RECRUITINGNANCT07293923Magenta Elevate™ Clinical Feasibility Study in Cardiogenic ShockMagenta Medical Ltd.
- RECRUITINGNCT07354568Prognosis of Patients With Mixed Cardiogenic-Vasoplegic ShockCentre Hospitalier Universitaire, Amiens
- RECRUITINGNCT06964685Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic ShockAbiomed Inc.